Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » EFSF Huge news

 - UBBFriend: Email this page to someone!    
Author Topic: EFSF Huge news
rider3160
Member


Rate Member
Icon 1 posted      Profile for rider3160         Edit/Delete Post   Reply With Quote 
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Oct. 12, 2005--
Patricia Ross-Gruden, President and Chief Executive
Officer of eFoodSafety.com, Inc. (OTCBB: EFSF), announced today that
the company signed a Distribution Agreement with NutraLab, Inc. to
conduct a Direct Response Marketing Campaign to sell Cinnergen(TM)
(www.cinnergen.com), a product formulated to assist the body in
metabolizing blood sugar. The total direct and indirect costs of
diabetes in the United States as calculated in 2002 were estimated by
the Centers for Disease Control and Prevention (CDC) at $132 Billion
and growing. Cinnergen(TM)'s all-natural formulation can supplement
prescriptive medication in Type 1 diabetic patients, can supplement
prescriptive medication and help decrease required levels of
medication in Type 2 diabetic and borderline patients, and with
regular use help normalize blood sugar levels and forestall
pre-diabetic individuals from developing complications of high blood
sugar.
Cinnergen(TM) is a once-a-day formula made from 15 whole foods
that contain no fats, carbohydrates, sugar, or calories. Cinnergen(TM)
is specially formulated to promote healthy glucose metabolism and to
decrease the symptoms that commonly accompany elevated blood sugar and
its effects.
As stated by the CDC, diabetes is a group of diseases described by
high levels of blood glucose resulting from defects in insulin
secretion, insulin action, or both. Diabetes can cause serious
complications and premature death, but persons with diabetes can take
measures to reduce the likelihood of such occurrences. Although more
than 18 million Americans have been diagnosed with diabetes,
approximately 5.2 million cases are undiagnosed, and an estimated 41
million U.S. adults aged 40-74 have prediabetes and are at high risk
for developing diabetes (www.cdc.gov/diabetes).
Cinnergen(TM) delivers concentrated nutrition to help the body
efficiently and effectively metabolize sugar. As a whole food complex,
Cinnergen provides several key ingredients that have been proven
clinically through years of research to improve digestion and
utilization of sugar, which are generally deficient in a typical
American diet.
"Again we are allying ourselves with proven products that aid in
the betterment of mankind, while being available for resale
immediately with no production or manufacturing lag time. As the CDC
states, many diabetic diagnoses can be prevented with early detection,
improved delivery of care, and better education on diabetes
self-management. eFoodSafety.com, Inc. is making available a
supplement that nourishes these millions of people while tapping into
a $132 billion market," stated Patricia Ross-Gruden, President and CEO
of eFoodSafety.com, Inc.
The company will initially focus on the Direct Response Marketing
Campaign over the next 60 days and subsequently will work toward
national distribution channels on the retail level.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving food and health
conditions around the world through its innovative technologies. The
company's Knock-Out Technologies, Ltd. subsidiary has developed an
environmentally safe sporicidal product formulated entirely of
food-grade components that eradicates anthrax and a germicidal product
that kills six major bacteria: E-coli, Listeria, Pseudomonas,
Salmonella, Staphylococcus, and Streptococcus, and avian influenza.
The sporicidal product has completed its final efficacy laboratory
study requisite for EPA registration; in the study, it eradicated both
Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on
both hard and porous surfaces. The company's MedElite, Inc. subsidiary
distributes clinically proven products to physicians who then
prescribe the products for their patients. It is the exclusive U.S.
and Worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has
been clinically proven to facilitate and improve the appearance,
redness and strength of scars (www.talsyn.com). The company has also
recently become a distributor for Cinnergen(TM), a non-prescription
liquid whole food nutritional supplement that promotes healthy glucose
metabolism (www.cinnergen.com).

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly
historical are "forward-looking" statements within the meaning of
Section 27A of the Securities Act of 1933 as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. The
forward-looking statements are made based on information available as
of the date hereof, and the company assumes no obligation to update
such forward-looking statements. Editors and investors are cautioned
that such forward-looking statements invoke risk and uncertainties and
the company's actual results may differ from these forward-looking
statements. Such risks and uncertainties include but are not limited
to demand for the company's products and services, our ability to
continue to develop markets, general economic conditions, our ability
to secure additional financing for the company and other factors that
may be more fully described in reports to shareholders and periodic
filings with the Securities and Exchange Commission.

Posts: 1423 | Registered: Jul 2005  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share